|
The investigation did not identify a product problem.A review of the internal data showed that the batch was released within specifications.Furthermore, a trend was not identified for the product.During the investigation, it was identified that controls were not included in the initial run but only included in the follow-up testing done on the benchmark ultra instrument (after the initial incorrect test results had been reported to the physician/patient), per the method sheet, control tissues are required to verify assay performance.Positive control tissue must be run for each set of test conditions and with every pathway anti-her2 (4b5) antibody staining procedure performed.The same tissue used for the positive tissue control may be used as the negative tissue control.Additionally, a negative reagent control must be run for every specimen to aid in the interpretation of results.A performance check was performed on the instrument to evaluate the instrument performance.It was reported that all test results were in specification, and no hardware adjustments were required.Per the field safety engineer, thin, white debris were found in the ez prep bulk reagent container.It was reported that decontamination had not been performed since march 2023.Biofilms can form as a result of unaddressed microbial contamination within the system.They are typically seen where water quality is insufficient and/or instrument maintenance schedules are not well adhered to.Based on the investigation and available information, the probable root cause for the false negative result is contamination in the benchmark ultra, due to a lack of adherence to the recommended maintenance and decontamination procedures.It is recommended that the customer continues utilizing adequate di water and following the guidance provided in the operator manual for quarterly decontamination of the instruments and bottles using a quaternary disinfectant.
|